Allyson Ocean, MD, discusses the impact of the phase III PRODIGE 24/CCTG PA.6 trial on patients with pancreatic cancer.
Allyson Ocean, MD, an associate attending physician, NewYork-Presbyterian Hospital, and associate professor of clinical medicine at Weill Cornell Medicine, discusses the impact of the phase III PRODIGE 24/CCTG PA.6 trial on patients with pancreatic cancer.
The phase III PRODIGE 24/CCTG PA.6 trial compared 2 chemotherapy regimens, FOLFIRINOX and gemcitabine, in the adjuvant setting for patients with pancreatic cancer, explains Ocean. Before the trial, the standard of care was gemcitabine alone or in combination with capecitabine; however, this trial showed positive results in favor of FOLFIRINOX as adjuvant therapy with the median overall survival approaching over 4 years, says Ocean.
This trial changed the standard of care for patients with pancreatic cancer. Now, there is a treatment regimen that has been shown to extend life significantly. Therefore, because of the significant survival advantage, eligible patients with pancreatic cancer should receive FOLFIRINOX over gemcitabine in the adjuvant setting, concludes Ocean.